Hangzhou Tigermed Consulting Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Hangzhou, Zhejiang and currently employs 10,185 full-time employees. The company went IPO on 2012-08-17. Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The firm operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The firm conducts its businesses in the domestic and overseas markets.
Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
6,561
6,603
7,384
7,085
5,213
3,192
Crecimiento de los Ingresos (YoY)
-4%
-11%
4%
36%
63%
14%
Costo de los ingresos
4,855
4,358
4,538
4,277
2,942
1,678
Utilidad bruta
1,706
2,244
2,845
2,808
2,270
1,514
Venta, General y Administración
965
860
782
722
652
435
Investigación y Desarrollo
257
229
254
229
211
151
Gastos de Operación
1,174
1,154
1,132
1,028
841
557
Otras Ingresos (Gastos) No Operativos
-8
0
1
2
-12
-4
Ingreso antes de impuestos
800
664
2,488
2,585
3,684
2,218
Gasto por Impuesto a la Renta
163
216
338
313
292
189
Ingreso Neto
612
405
2,024
2,006
2,874
1,749
Crecimiento de la Utilidad Neta
-36%
-80%
1%
-30%
64%
108%
Acciones en Circulación (Diluidas)
868.8
863.04
865.32
864.89
870.95
799
Cambio de Acciones (YoY)
0%
0%
0%
-1%
9%
7%
EPS (Diluido)
0.7
0.46
2.34
2.32
3.3
2.19
Crecimiento de EPS
-36%
-80%
1%
-30%
51%
94%
Flujo de efectivo libre
1,005
740
836
908
1,055
842
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
26%
33.98%
38.52%
39.63%
43.54%
47.43%
Margen de operación
8.09%
16.49%
23.18%
25.1%
27.41%
29.94%
Margen de beneficio
9.32%
6.13%
27.41%
28.31%
55.13%
54.79%
Margen de flujo de caja libre
15.31%
11.2%
11.32%
12.81%
20.23%
26.37%
EBITDA
--
1,241
1,838
1,889
1,500
1,013
Margen de EBITDA
--
18.79%
24.89%
26.66%
28.77%
31.73%
D&A para EBITDA
--
152
126
110
71
57
EBIT
531
1,089
1,712
1,779
1,429
956
Margen de EBIT
8.09%
16.49%
23.18%
25.1%
27.41%
29.94%
Tasa de Impuesto Efectiva
20.37%
32.53%
13.58%
12.1%
7.92%
8.52%
Follow-Up Questions
¿Cuáles son los estados financieros clave de Hangzhou Tigermed Consulting Co., Ltd?
Según el último estado financiero (Form-10K), Hangzhou Tigermed Consulting Co., Ltd tiene un total de activos de $28,671, una ganancia neta ganancia de $405
¿Cuáles son los ratios financieros clave para HNGZY?
El ratio corriente de Hangzhou Tigermed Consulting Co., Ltd es 3.58, el margen neto es 6.13, las ventas por acción son $7.65.
¿Cómo se desglosan los ingresos de Hangzhou Tigermed Consulting Co., Ltd por segmento o geografía?
El segmento de ingresos más grande es Hangzhou Tigermed Consulting Co., Ltd, con unos ingresos de Clinical Trial Technical Services en el último informe de ganancias. En cuanto a la geografía, China es el mercado principal para Hangzhou Tigermed Consulting Co., Ltd, con unos ingresos de 4,234,516,020.